CellSaic, A Cell Aggregate-Like Technology Using Recombinant Peptide Pieces for MSC Transplantation

Author(s): Kentaro Nakamura*.

Journal Name: Current Stem Cell Research & Therapy

Volume 14 , Issue 1 , 2019

Become EABM
Become Reviewer

Abstract:

In the field of stem cell therapy, research on the application of mesenchymal stem cells (MSCs) has flourished because of the various functions. On the other hand, research on the method of cell transplantation has developed from the administration of cell suspensions to cell-sheet engineering and 3D technology. In the trend, a cell transplantation platform named CellSaic, which is a combination of xeno-free recombinant scaffolds in a cell aggregate-like shape, was developed. CellSaic is the cell transplantation platform that can prevent the central necrosis within cell aggregates by arranging the cells and petaloid pieces of recombinant peptide (RCP) in a mosaic. The prevention of central necrosis is the most significant advantage over other 3D culture systems. This review details the unique characteristics of CellSaic including safety examination results and describes its future application for MSC transplantation. Particularly, in the application of MSCs, it has been reported that the MSC CellSaics increased the effect on improving various symptoms compared with MSCs only in the application of the therapy to inflammatory bowel disease (IBD), cerebral infarction, bone cartilage regeneration in joints, and islet transplantation. In accordance with the “One Health” concept, it is anticipated that this technology is expected to contribute to companion animal therapy and human therapy in the future.

Keywords: MSC, Recombinant peptide (RCP), Cell transplantation, mesenchymal stem cells, inflammatory bowel disease (IBD), CellSaic.

[1]
Langer R and, Vacanti JP. Tissue engineering. Science 1993; 260(5110): 920-6.
[2]
Nerem RM, Sambanis A. Tissue engineering: from biology to biological substitutes. Tissue Eng 1995; 1(1): 3-13.
[3]
Peter SJ, Miller MJ, Yasko AW, Yaszemski MJ, Mikos AG. Polymer concepts in tissue engineering. J Biomed Mater Res 1998; 43(4): 422-7.
[4]
Shoichet MS, Hubbell JA. Polymers for tissue engineering. J Biomater Sci 1998; 9(5): 405-6.
[5]
Chen G, Ushida T, Tateishi T. Scaffold design for tissue engineering. Macromol Biosci 2002; 2(2): 67-77.
[6]
Halme DG, Kessler DA. FDA regulation of stem-cell-based therapies. N Engl J Med 2006; 355(16): 1730-5.
[7]
Cimino M, Goncalves RM, Barrias CC, Martins MCL. Xeno-free strategies for safe human mesenchymal stem/stromal cell expansion: supplements and coatings. Stem Cells Int 2017; 6597815: 1-13.
[8]
Richards M, Fong CY, Tan S, Chan WK, Bongso A. An efficient and safe xeno‐free cryopreservation method for the storage of human embryonic stem cells. Nature 1953; 171(4356): 737-8.
[9]
Trounson A, Thakar RG, Lomax G, Gibbons D. Clinical trials for stem cell therapies. BMC Med 2011; 9(52): 1-7.
[10]
Galipeau J, Sensebe L. Mesenchymal stromal cells: Clinical challenges and taherapeutic opportunities. Cell Stem Cell 2018; 22(6): 824-33.
[11]
Ko IK, Kim BG, Awadallah A, et al. Targeting improves MSC treatment of inflammatory bowel disease. Mol Ther 2010; 18(7): 1365-72.
[12]
Caplan AI. Review: Mesenchymal stem cells: Cell based reconstructive therapy in orthopedics. Tissue Eng 2005; 11(7-8): 1198-211.
[13]
Nitkin CR, Bonfield TL. Concise review: Mesenchymal stem cell therapy for pediatric disease: Perspectives on success and potential improvements. Stem Cells Transl Med 2017; 6(2): 539-65.
[14]
Jurado M, Gil AC, Mata C, et al. A multicenter randomized clinical trial evaluating the safety and feasibility of the treatment of GvHD with allogenic Mesenchymal Stem Cells (MSC) from adipose tissue. Cytotherapy 2017; 19(5): S11.
[15]
Ringdén O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006; 81(10): 1390-7.
[16]
Bahr L, Sundberg B, Lönnies L, et al. Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol Blood Marrow Transplant 2012; 18(4): 557-64.
[17]
Bhasin A, Srivastava MV, Mohanty S, et al. Stem cell therapy: A clinical trial of stroke. Clin Neurol Neurosurg 2013; 115(7): 1003-8.
[18]
Wechsler LR, Bates D, Stroemer P, Andrews-Zwilling YS, Aizman I. Cell therapy for chronic stroke. Stroke 2018; 49(5): 1066-74.
[19]
Amado LC, Saliaris AP, Schuleri KH, et al. Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci USA 2005; 102(32): 11474-9.
[20]
Martin-Rendon E, Gyongyosi M. Mesenchymal stromal cell therapy as treatment for ischemic heart failure: the MSC-HF study. Cardiovasc Diagn Ther 2017; 7(Suppl. 2): S69-72.
[21]
Volk SW, Theoret C. Translating stem cell therapies: the role of companion animals in regenerative medicine. Wound Repair Regen 2013; 21(3): 382-94.
[22]
Kahn LH, Kaplan B, Monath TP, Steele JH. Teaching “one medicine, one health”. Am J Med 2008; 121(3): 169-70.
[23]
One Health Initiative. [Internet] 2012; cited Dec 12. Available from. www.onehealthinitiative.com
[24]
Yamato M, Okano T. Cell sheet engineering. Materialstoday 2004; 7(5): 42-7.
[25]
Baksh N, Gallant ND, Toomey RG. Cell sheet engineering for integrating functional tissue in vivo: Successes and challenges. MRS Bulletin 2017; 42(5): 350-5.
[26]
Baraniak PR, McDevitt TC. Scaffold-free culture of mesenchymal stem cell spheroids in suspension preserves multilineage potential. Cell Tissue Res 2012; 347(3): 701-11.
[27]
Ylostalo JH, Bazhanov Mohammadipoor N, Bartosh TJ. Production and administration of therapeutic mesenchymal stem/stromal cell (msc) spheroids primed in 3-D cultures under Xeno-free conditions. J Vis Exp 2017; 18(121)
[http://dx.doi.org/10.3791/55126]
[28]
Yanagihara K, Uchida S, Ohba S, Kataoka K, Itaka K. Treatment of Bone Defects by Transplantation of Genetically Modified Mesenchymal Stem Cell Spheroids. Mol Ther Methods Clin Dev 2018; 9(15): 358-66.
[29]
Nakamura K, Iwazawa R, Yoshioka Y. Introduction to a new cell transplantation platform via recombinant peptide petaloid pieces and its application to islet transplantation with mesenchymal stem cells. Transpl Int 2016; 29(9): 1039-50.
[30]
Nakamura K. Cell construct comprising polymer blocks having biocompatibility and cells. US Patent 2010; US9,597,432
[31]
Nakamura K, Tabata Y. A new fluorescent imaging of renal inflammation with RCP. J Control Release 2010; 148(3): 351-8.
[32]
Nakamura K, Iwazawa R, Miyoshi H, et al. Cell structure for cell transplantation, biocompatible polymer block, and methods for producing same International patent publication No 2013; WO/2014/133081
[33]
Iwazawa R, Kozakai S, Kitahashi T, Nakamura K, Hata K. The therapeutic effects of adipose-derived stem cells and recombinant peptide pieces on mouse model of DSS colitis. Cell Transplant 2018. [Epub ahead of print].
[34]
Kozakai S, Nakamura K. Trophic factor release agent and inflammatory disease treatment agent International patent publication No 2016; WO2017/221879
[35]
Recommendations for the evaluation of animal cell cultures as substrates for the manufacture of biological medicinal products and for the characterization of cell banks. WHO technical report series, No 978 Annex 3 2013.
[36]
Nakamura K. Cell structure for use in treatment of brain injury, method for producing same, and therapeutic agent for brain injuryInternational patent publication No 2014; WO2015/194494
[37]
Miyamoto M, Nakamura K, Shichinohe H, et al. Human Recombinant Peptide Sponge Enables Novel, Less Invasive Cell Therapy for Ischemic Stroke. Stem Cells Int 2018; 4829534: 1-8.
[38]
Naritomi M, Mizuno M, Katano H, et al. Petaloid recombinant peptide enhances in vitro cartilage formation by synovial mesenchymal stem cells. J Orthop Res 2018. In press
[39]
Nakamura K, Miyoshi H, Hada S, Watanabe M. Cartilage-regenerating material International patent publication No 2015; WO2016/148245
[40]
Nakamura K, Mima S, Kitahashi T, Kakimuma C. Cell structure, non-human mode animal, method for producing non-human model animal, and method for evaluating test substanceInternational patent publication No 2015; WO/2017/022613
[41]
Nakamura K. Method for manufacturing sheet-shaped cell structure, and sheet-shaped cell structureInternational patent publication No 2015; WO/2017/057547
[42]
Nakamura K. Tublar structure, device for producing tubular structure, and method for producing tubular structureInternational patent publication No 2014; WO/2016/068292
[43]
Nakamura K, Kuchiishi K, Kizawa H, Aburaya A. Tubular structure, method for producing cell structure, and method for producing tubular structure. Japan patent publication NO 2015. P2016- 174538A.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 14
ISSUE: 1
Year: 2019
Page: [52 - 56]
Pages: 5
DOI: 10.2174/1574888X13666180912125157

Article Metrics

PDF: 26
HTML: 3